Drug Profile

Research programme: neuromuscular disease therapeutics - Avidity Biosciences

Alternative Names: Rare neuromuscular disease therapeutics - Avidity Biosciences

Latest Information Update: 31 Mar 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Avidity Biosciences
Class Drug conjugates; Immunoconjugates; Monoclonal antibodies; Oligonucleotides; Small interfering RNA
Mechanism of Action RNA interference

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes
Available For Licensing Yes

17 Mar 2025 Research programme: neuromuscular disease therapeutics - Avidity Biosciences is available for licensing as of 17 Mar 2025. https://www.aviditybiosciences.com/pipeline/collaborations-and-partnerships/
17 Mar 2025 Preclinical trials in Neuromuscular disorders in USA (unspecified route) (Avidity Biosciences pipeline, March,

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com